Eledon Prescription drugs, Inc. (ELDN) Discusses Section II BESTOW Trial Outcomes and Advances in Transplantation Immunosuppression Transcript07/11/2025
Share Facebook Twitter LinkedIn Pinterest Email Cullinan Therapeutics: Betting On Zipalertinib NDA CatalystLike this:Like Loading...Related Betting Catalyst Cullinan NDA Therapeutics Zipalertinib
Eledon Prescription drugs, Inc. (ELDN) Discusses Section II BESTOW Trial Outcomes and Advances in Transplantation Immunosuppression Transcript07/11/2025
The PNC Monetary Providers Group, Inc. (PNC) Presents at The BancAnalysts Affiliation of Boston Convention Transcript07/11/2025
